SLC28A2: A Potential Drug Target for Neurodegenerative Diseases

Target Name: SLC28A2

NCBI ID: G9153

SLC28A2: A Potential Drug Target for Neurodegenerative Diseases

SLC28A2 (hCNT2) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the sodium channel subfamily 28, which is a family of voltage-dependent sodium channels that play a crucial role in the regulation of ion channels in the nervous system and other tissues.

One of the unique features of SLC28A2 is its ability to interact with other proteins, particularly the neurotransmitter nicotine. Studies have shown that SLC28A2 is a receptor for nicotine, which means that it can bind to the nicotine molecule and trigger various physiological responses within the body.

SLC28A2 has also been shown to play a role in the regulation of ion channels in the brain, which is particularly relevant to the development and progression of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Studies have shown that alterations in SLC28A2 levels or function can contribute to the development of these conditions, and that targeting this protein may be a potential therapeutic approach.

In addition to its potential role in neurodegenerative diseases, SLC28A2 is also a potential drug target. The high level of expression of SLC28A2 in various tissues and the fact that it is a receptor for nicotine make it an attractive target for drug development. Studies have shown that SLC28A2 can be modulated by various drug treatments, including those that target ion channels and neurotransmitters.

The biology of SLC28A2 is also of interest to researchers studying the regulation of ion channels in the nervous system. SLC28A2 is known to play a role in the regulation of Na+ and K+ channels, which are critical for the transmission of electrical signals in the nervous system. The alteration of SLC28A2 levels or function can affect the regulation of these channels, which can have implications for the development and progression of neurodegenerative diseases.

In conclusion, SLC28A2 is a protein that has significant interest in the development and progression of neurodegenerative diseases. Its ability to interact with nicotine and its role in the regulation of ion channels in the brain make it a potential drug target. Further research is needed to fully understand the biology of SLC28A2 and its potential as a therapeutic approach.

Protein Name: Solute Carrier Family 28 Member 2

Functions: Sodium-dependent and purine-selective transporter (PubMed:9435697, PubMed:10087507). Exhibits the transport characteristics of the nucleoside transport system cif or N1 subtype (N1/cif) (selective for purine nucleosides and uridine) (PubMed:9435697, PubMed:10087507, PubMed:21795683). Plays a critical role in specific uptake and salvage of purine nucleosides in kidney and other tissues (PubMed:9435697). May contribute to regulate the transport of organic compounds in testes across the blood-testis-barrier (Probable)

More Common Targets